Recon: Eli Lilly to buy Morphic for $3.2 billion; White House appeals patent decision on HIV preventives

• Eli Lilly to acquire Morphic for $3.2 billion (STAT)
• Biden administration appeals jury finding in battle over patents for HIV prevention pills (STAT)
• News We’re Watching: FDA Issues Monkeypox EUAs, IMDRF Publishes AI Principes, Quest Buys LifeLabs (MedTech Insight)
• J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market (Fierce Pharma)
• Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration (Fierce Pharma)
• US FDA Advisory Committee Open Public Hearing Changes Urged (Pink Sheet)
• Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight (FDA Law Blog)

• U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer (STAT)
• Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector (Reuters)
• BD to close Ireland facility, putting 170 jobs at risk (MedTech Dive)
• UK Regulation: In A System Of Regulatory Reliance, PMS Assumes A Central Role (MedTech Insight)
• MDCG 2021-5 Rev. 1: EU’s Standardization Guidance Brought Up To Date (MedTech Insight)
• EU Regulators Call For More Registrations To Help Unlock Real-World Data Potential (Pink Sheet)
• Novartis’ Gene Therapy Luxturna Gets Routine Funding In Scotland (Pink Sheet)

• The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades (STAT)
• Infections are major cause of non-relapse deaths after CAR-T cell therapy, study shows (Endpoints)
• Exclusive: Gene insertion startup launches with new integrase technology from University of Hawaii (Endpoints)
• HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants (Endpoints)
• Vanqua raises $45M; Aerovate to look for strategic alternatives (Endpoints)
• Ideaya showcases proof-of-concept data in a boost to synthetic lethality play (Endpoints)
• Masimo receives offer of up to $950 mln for consumer business (Reuters)
• Novo's Ozempic, Wegovy linked to potential eye problem? Not so fast, analysts say (Fierce Pharma)

• AI leads the way as health tech funding inches toward a post-pandemic stability (STAT)
• Digital health deals rallied in the first half of 2024, though funding still trails last year (Endpoints)
• Carlyle in Advanced Talks to Acquire Baxter’s Vantive (WSJ)
• Quest to buy Lifelabs for $985M (MedTech Dive)
• Deals Shaping The Medtech And Diagnostics Industries, June 2024 (MedTech Insight)

• Steward Health Care spent millions on surveillance of its critics — even amid financial crisis (STAT)
• EcoHealth Alliance: Covid’s anti-science mob extracting its pound of flesh (STAT)
• J&J, Arcutis back educational video series about how skin conditions affect people of color (Fierce Pharma)